SEC Form 4 · accession 0001104659-26-108246
Cytosorbents Corp · CTSO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alan D. Sobel
Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 16, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001175151
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Sep 15, 2026 | P | 1,900 | $6.12 | A | 9,287 | D | |
| Common StockF1,F2,F3 | Sep 15, 2026 | P | 500 | $6.05 | A | 9,787 | D | |
| Common StockF1,F2,F3 | Sep 15, 2026 | P | 100 | $6.01 | A | 9,887 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These transactions reported on this Form 4 reflect open market purchases made by the Reporting Person.
- F2Includes (i) the following restricted stock units ("RSUs") that will be settled into Common Stock upon vesting upon a "Change in Control" of CytoSorbents Corporation (the "Issuer"), as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 165 RSUs granted on March 15, 2018, (b) 300 RSUs granted on February 24, 2017, (c) 250 RSUs granted on June 7, 2016, and (d) 2,750 RSUs granted on April 8, 2015 and (ii) 6,422 shares of Common Stock owned directly by the Reporting Person.
- F3Reflects the 1-for-20 reverse stock split effected by the Issuer on September 8, 2026.